Мика ХелпПАЦИЕНТАМ И ВРАЧАМ · СПРАВОЧНИК
Хронический лимфолейкоз
Русские главы, оригинальный обзор NCI и его библиография. Научные источники открываются непосредственно в новой вкладке.
Прочитать на русском
Ниже — главы справочника, в которых разобраны темы этого обзора: выбор лечения, роль операции, ограничения и восстановление. Близкие редкие диагнозы могут быть объединены в одной главе с отдельными разделами.
Хронические лейкозы и роль хирургии →Первоисточник и дополнительные подробности
Chronic Lymphocytic Leukemia Treatment (PDQ®) - NCI
Открыть оригинальный обзор NCI → (откроется в новой вкладке)Источник на английском языке. Он рассматривает заболевание в целом, включая методы, выходящие за рамки хирургии. Наш сайт не является изданием NCI и не представляет перевод, утверждённый NCI.
Дата последнего обновления, указанная в исходном обзоре: 04/25/2025 (месяц/день/год).
Ссылка и библиографический список извлечены: 2026-09-10. Это не дата проверки каждой публикации.
Библиография · 185 публикаций
Anaissie EJ, Kontoyiannis DP, O'Brien S, et al.: Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129 (7): 559-66, 1998. (откроется в новой вкладке)
Mauro FR, Foa R, Cerretti R, et al.: Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 95 (9): 2786-92, 2000. (откроется в новой вкладке)
Hallek M, Cheson BD, Catovsky D, et al.: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131 (25): 2745-2760, 2018. (откроется в новой вкладке)
Hallek M, Cheson BD, Catovsky D, et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111 (12): 5446-56, 2008. (откроется в новой вкладке)
Shanafelt TD, Kay NE, Jenkins G, et al.: B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 113 (18): 4188-96, 2009. (откроется в новой вкладке)
Rawstron AC, Bennett FL, O'Connor SJ, et al.: Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 359 (6): 575-83, 2008. (откроется в новой вкладке)
Dighiero G: Monoclonal B-cell lymphocytosis--a frequent premalignant condition. N Engl J Med 359 (6): 638-40, 2008. (откроется в новой вкладке)
Fazi C, Scarfò L, Pecciarini L, et al.: General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood 118 (25): 6618-25, 2011. (откроется в новой вкладке)
DiGiuseppe JA, Borowitz MJ: Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 25 (1): 6-10, 1998. (откроется в новой вкладке)
Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 333 (16): 1052-7, 1995. (откроется в новой вкладке)
Landgren O, Albitar M, Ma W, et al.: B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 360 (7): 659-67, 2009. (откроется в новой вкладке)
Hoyer JD, Ross CW, Li CY, et al.: True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood 86 (3): 1163-9, 1995. (откроется в новой вкладке)
Strati P, Shanafelt TD: Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 126 (4): 454-62, 2015. (откроется в новой вкладке)
Shim YK, Rachel JM, Ghia P, et al.: Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding. Blood 123 (9): 1319-26, 2014. (откроется в новой вкладке)
Slager SL, Lanasa MC, Marti GE, et al.: Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. Blood 137 (15): 2046-2056, 2021. (откроется в новой вкладке)
Shanafelt TD, Kay NE, Rabe KG, et al.: Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol 27 (24): 3959-63, 2009. (откроется в новой вкладке)
Slager SL, Parikh SA, Achenbach SJ, et al.: Progression and survival of MBL: a screening study of 10 139 individuals. Blood 140 (15): 1702-1709, 2022. (откроется в новой вкладке)
Sokol L, Loughran TP: Large granular lymphocyte leukemia. Oncologist 11 (3): 263-73, 2006. (откроется в новой вкладке)
Semenzato G, Zambello R, Starkebaum G, et al.: The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood 89 (1): 256-60, 1997. (откроется в новой вкладке)
Lamy T, Loughran TP: How I treat LGL leukemia. Blood 117 (10): 2764-74, 2011. (откроется в новой вкладке)
Bowman SJ, Sivakumaran M, Snowden N, et al.: The large granular lymphocyte syndrome with rheumatoid arthritis. Immunogenetic evidence for a broader definition of Felty's syndrome. Arthritis Rheum 37 (9): 1326-30, 1994. (откроется в новой вкладке)
Koskela HL, Eldfors S, Ellonen P, et al.: Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366 (20): 1905-13, 2012. (откроется в новой вкладке)
Cheon H, Xing JC, Moosic KB, et al.: Genomic landscape of TCRαβ and TCRγδ T-large granular lymphocyte leukemia. Blood 139 (20): 3058-3072, 2022. (откроется в новой вкладке)
Barilà G, Grassi A, Cheon H, et al.: Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients. Blood 141 (9): 1036-1046, 2023. (откроется в новой вкладке)
Loughran TP, Kidd PG, Starkebaum G: Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 84 (7): 2164-70, 1994. (откроется в новой вкладке)
Dhodapkar MV, Li CY, Lust JA, et al.: Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 84 (5): 1620-7, 1994. (откроется в новой вкладке)
Developments in the treatment of lymphoproliferative disorders: rising to the new challenges of CLL therapy. A report of a symposium presented during the 48th American Society of Hematology Annual Meeting and Exposition, December 8, 2006, Orlando, Florida. Clin Adv Hematol Oncol 5 (3 Suppl 5): 1-14; quiz 15-6, 2007. (откроется в новой вкладке)
Pflug N, Bahlo J, Shanafelt TD, et al.: Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 124 (1): 49-62, 2014. (откроется в новой вкладке)
Döhner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (26): 1910-6, 2000. (откроется в новой вкладке)
Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 (6): 1848-54, 1999. (откроется в новой вкладке)
Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 (6): 1840-7, 1999. (откроется в новой вкладке)
Rosenwald A, Alizadeh AA, Widhopf G, et al.: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194 (11): 1639-47, 2001. (откроется в новой вкладке)
Klein U, Tu Y, Stolovitzky GA, et al.: Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194 (11): 1625-38, 2001. (откроется в новой вкладке)
Orchard JA, Ibbotson RE, Davis Z, et al.: ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363 (9403): 105-11, 2004. (откроется в новой вкладке)
Rassenti LZ, Huynh L, Toy TL, et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (9): 893-901, 2004. (откроется в новой вкладке)
Kröber A, Bloehdorn J, Hafner S, et al.: Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 24 (6): 969-75, 2006. (откроется в новой вкладке)
Byrd JC, Gribben JG, Peterson BL, et al.: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 24 (3): 437-43, 2006. (откроется в новой вкладке)
Kharfan-Dabaja MA, Chavez JC, Khorfan KA, et al.: Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. Cancer 113 (5): 897-906, 2008. (откроется в новой вкладке)
Kröber A, Seiler T, Benner A, et al.: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100 (4): 1410-6, 2002. (откроется в новой вкладке)
Catovsky D, Fooks J, Richards S: Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol 72 (2): 141-9, 1989. (откроется в новой вкладке)
Shanafelt TD, Witzig TE, Fink SR, et al.: Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 24 (28): 4634-41, 2006. (откроется в новой вкладке)
Grever MR, Lucas DM, Dewald GW, et al.: Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25 (7): 799-804, 2007. (откроется в новой вкладке)
Catovsky D, Richards S, Matutes E, et al.: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370 (9583): 230-9, 2007. (откроется в новой вкладке)
Binet JL, Caligaris-Cappio F, Catovsky D, et al.: Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107 (3): 859-61, 2006. (откроется в новой вкладке)
Rai KR, Sawitsky A, Cronkite EP, et al.: Clinical staging of chronic lymphocytic leukemia. Blood 46 (2): 219-34, 1975. (откроется в новой вкладке)
Binet JL, Auquier A, Dighiero G, et al.: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48 (1): 198-206, 1981. (откроется в новой вкладке)
Falchi L, Keating MJ, Marom EM, et al.: Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood 123 (18): 2783-90, 2014. (откроется в новой вкладке)
Montserrat E, Sanchez-Bisono J, Viñolas N, et al.: Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 62 (3): 567-75, 1986. (откроется в новой вкладке)
Di Giovanni S, Valentini G, Carducci P, et al.: Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol 81 (4): 181-5, 1989. (откроется в новой вкладке)
Parikh SA, Kay NE, Shanafelt TD: How we treat Richter syndrome. Blood 123 (11): 1647-57, 2014. (откроется в новой вкладке)
Rossi D, Spina V, Deambrogi C, et al.: The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 117 (12): 3391-401, 2011. (откроется в новой вкладке)
Kittai AS, Bond D, Huang Y, et al.: Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol 42 (17): 2071-2079, 2024. (откроется в новой вкладке)
Al-Sawaf O, Robrecht S, Bahlo J, et al.: Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia 35 (1): 169-176, 2021. (откроется в новой вкладке)
Stephens DM, Boucher K, Kander E, et al.: Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica 106 (11): 2845-2852, 2021. (откроется в новой вкладке)
Böttcher S, Ritgen M, Fischer K, et al.: Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30 (9): 980-8, 2012. (откроется в новой вкладке)
Strati P, Keating MJ, O'Brien SM, et al.: Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 123 (24): 3727-32, 2014. (откроется в новой вкладке)
Montserrat E, Moreno C, Esteve J, et al.: How I treat refractory CLL. Blood 107 (4): 1276-83, 2006. (откроется в новой вкладке)
Ghia P, Guida G, Stella S, et al.: The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101 (4): 1262-9, 2003. (откроется в новой вкладке)
Tsimberidou AM, Wen S, McLaughlin P, et al.: Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 27 (6): 904-10, 2009. (откроется в новой вкладке)
Solomon BM, Rabe KG, Slager SL, et al.: Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol 31 (7): 930-7, 2013. (откроется в новой вкладке)
International CLL-IPI working group: An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 17 (6): 779-90, 2016. (откроется в новой вкладке)
Condoluci A, Terzi di Bergamo L, Langerbeins P, et al.: International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood 135 (21): 1859-1869, 2020. (откроется в новой вкладке)
Kreuzberger N, Damen JA, Trivella M, et al.: Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. Cochrane Database Syst Rev 7: CD012022, 2020. (откроется в новой вкладке)
Eichhorst BF, Fischer K, Fink AM, et al.: Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood 117 (6): 1817-21, 2011. (откроется в новой вкладке)
Moreno C, Hodgson K, Ferrer G, et al.: Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 116 (23): 4771-6, 2010. (откроется в новой вкладке)
Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med 110 (3): 236-8, 1989. (откроется в новой вкладке)
Gribben JG, O'Brien S: Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 29 (5): 544-50, 2011. (откроется в новой вкладке)
Wierda WG, O'Brien S, Wang X, et al.: Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109 (11): 4679-85, 2007. (откроется в новой вкладке)
Del Giudice I, Chiaretti S, Tavolaro S, et al.: Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood 114 (3): 638-46, 2009. (откроется в новой вкладке)
Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 91 (10): 861-8, 1999. (откроется в новой вкладке)
Ritgen M, Stilgenbauer S, von Neuhoff N, et al.: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104 (8): 2600-2, 2004. (откроется в новой вкладке)
Moreno C, Villamor N, Colomer D, et al.: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23 (15): 3433-8, 2005. (откроется в новой вкладке)
Khouri IF, Keating MJ, Saliba RM, et al.: Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4 (3): 217-21, 2002. (откроется в новой вкладке)
Doney KC, Chauncey T, Appelbaum FR, et al.: Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant 29 (10): 817-23, 2002. (откроется в новой вкладке)
Pavletic SZ, Khouri IF, Haagenson M, et al.: Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol 23 (24): 5788-94, 2005. (откроется в новой вкладке)
Thompson PA, Tam CS, O'Brien SM, et al.: Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127 (3): 303-9, 2016. Cited in: Selection of Therapy for Chronic Lymphocytic Leukemia (откроется в новой вкладке)
Fischer K, Bahlo J, Fink AM, et al.: Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127 (2): 208-15, 2016. (откроется в новой вкладке)
Rossi D, Terzi-di-Bergamo L, De Paoli L, et al.: Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood 126 (16): 1921-4, 2015. (откроется в новой вкладке)
Burger JA, Tedeschi A, Barr PM, et al.: Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 373 (25): 2425-37, 2015. (откроется в новой вкладке)
Cramer P, Tausch E, von Tresckow J, et al.: Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. Blood 138 (19): 1805-1816, 2021. (откроется в новой вкладке)
Eichhorst B, Fink AM, Bahlo J, et al.: First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17 (7): 928-942, 2016. (откроется в новой вкладке)
Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med 319 (14): 902-7, 1988. (откроется в новой вкладке)
Griffiths H, Brennan V, Lea J, et al.: Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 73 (2): 366-8, 1989. (откроется в новой вкладке)
Weeks JC, Tierney MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 325 (2): 81-6, 1991. (откроется в новой вкладке)
Mato AR, Roeker LE, Lamanna N, et al.: Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood 136 (10): 1134-1143, 2020. (откроется в новой вкладке)
Scarfò L, Chatzikonstantinou T, Rigolin GM, et al.: COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 34 (9): 2354-2363, 2020. (откроется в новой вкладке)
Kaufman M, Limaye SA, Driscoll N, et al.: A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma 50 (6): 892-9, 2009. (откроется в новой вкладке)
Cheson BD, Frame JN, Vena D, et al.: Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 16 (7): 2313-20, 1998. (откроется в новой вкладке)
Maddocks-Christianson K, Slager SL, Zent CS, et al.: Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol 139 (3): 398-404, 2007. (откроется в новой вкладке)
Visentin A, Bonaldi L, Rigolin GM, et al.: The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica 107 (4): 868-876, 2022. (откроется в новой вкладке)
Chigrinova E, Rinaldi A, Kwee I, et al.: Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 122 (15): 2673-82, 2013. (откроется в новой вкладке)
Parry EM, Leshchiner I, Guièze R, et al.: Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med 29 (1): 158-169, 2023. (откроется в новой вкладке)
Parry EM, Ten Hacken E, Wu CJ: Richter syndrome: novel insights into the biology of transformation. Blood 142 (1): 11-22, 2023. (откроется в новой вкладке)
Robertson LE, Pugh W, O'Brien S, et al.: Richter's syndrome: a report on 39 patients. J Clin Oncol 11 (10): 1985-9, 1993. (откроется в новой вкладке)
Jain N, Keating M, Thompson P, et al.: Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380 (22): 2095-2103, 2019. (откроется в новой вкладке)
Ben-Dali Y, Hleuhel MH, da Cunha-Bang C, et al.: Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study. Leuk Lymphoma 61 (6): 1435-1444, 2020. (откроется в новой вкладке)
Abdel-Qadir H, Sabrie N, Leong D, et al.: Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. J Clin Oncol 39 (31): 3453-3462, 2021. (откроется в новой вкладке)
Byrd JC, Hillmen P, Ghia P, et al.: Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol 39 (31): 3441-3452, 2021. (откроется в новой вкладке)
Molica S, Giannarelli D, Gentile M, et al.: External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. Cancer 119 (6): 1177-85, 2013. (откроется в новой вкладке)
Kwok M, Oldreive C, Rawstron AC, et al.: Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. Blood 135 (6): 411-428, 2020. (откроется в новой вкладке)
Dighiero G, Maloum K, Desablens B, et al.: Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 338 (21): 1506-14, 1998. (откроется в новой вкладке)
Byrd JC, Furman RR, Coutre SE, et al.: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369 (1): 32-42, 2013. (откроется в новой вкладке)
O'Brien S, Furman RR, Coutre S, et al.: Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 131 (17): 1910-1919, 2018. (откроется в новой вкладке)
O'Brien S, Jones JA, Coutre SE, et al.: Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 17 (10): 1409-1418, 2016. (откроется в новой вкладке)
Stilgenbauer S, Eichhorst B, Schetelig J, et al.: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17 (6): 768-78, 2016. (откроется в новой вкладке)
Stilgenbauer S, Eichhorst B, Schetelig J, et al.: Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol 36 (19): 1973-1980, 2018. (откроется в новой вкладке)
Brown JR, Eichhorst B, Hillmen P, et al.: Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 388 (4): 319-332, 2023. (откроется в новой вкладке)
Seymour JF, Byrd JC, Ghia P, et al.: Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood 142 (8): 687-699, 2023. (откроется в новой вкладке)
Bhat SA, Gambril J, Azali L, et al.: Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood 140 (20): 2142-2145, 2022. (откроется в новой вкладке)
Woyach JA, Ruppert AS, Heerema NA, et al.: Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379 (26): 2517-2528, 2018. (откроется в новой вкладке)
Burger JA, Sivina M, Jain N, et al.: Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133 (10): 1011-1019, 2019. (откроется в новой вкладке)
Shanafelt TD, Wang XV, Kay NE, et al.: Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med 381 (5): 432-443, 2019. Cited in: Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia (откроется в новой вкладке)
Shanafelt TD, Wang XV, Hanson CA, et al.: Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 140 (2): 112-120, 2022. (откроется в новой вкладке)
Wang XV, Hanson CA, Tschumper RC, et al.: Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood 138 (26): 2810-2827, 2021. (откроется в новой вкладке)
Tam CS, Brown JR, Kahl BS, et al.: Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol 23 (8): 1031-1043, 2022. (откроется в новой вкладке)
Sharman JP, Egyed M, Jurczak W, et al.: Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395 (10232): 1278-1291, 2020. (откроется в новой вкладке)
Al-Sawaf O, Robrecht S, Zhang C, et al.: Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood 144 (18): 1924-1935, 2024. (откроется в новой вкладке)
Seymour JF, Kipps TJ, Eichhorst B, et al.: Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 378 (12): 1107-1120, 2018. Cited in: Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia (откроется в новой вкладке)
Kater AP, Seymour JF, Hillmen P, et al.: Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol 37 (4): 269-277, 2019. (откроется в новой вкладке)
Seymour JF, Kipps TJ, Eichhorst BF, et al.: Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood 140 (8): 839-850, 2022. (откроется в новой вкладке)
Munir T, Cairns DA, Bloor A, et al.: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. N Engl J Med 390 (4): 326-337, 2024. (откроется в новой вкладке)
Niemann CU, Munir T, Moreno C, et al.: Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 24 (12): 1423-1433, 2023. (откроется в новой вкладке)
Brown JR, Seymour JF, Jurczak W, et al.: Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. N Engl J Med 392 (8): 748-762, 2025. (откроется в новой вкладке)
Wierda WG, Allan JN, Siddiqi T, et al.: Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol 39 (34): 3853-3865, 2021. (откроется в новой вкладке)
Hillmen P, Rawstron AC, Brock K, et al.: Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. J Clin Oncol 37 (30): 2722-2729, 2019. (откроется в новой вкладке)
Tam CS, Allan JN, Siddiqi T, et al.: Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 139 (22): 3278-3289, 2022. (откроется в новой вкладке)
Huber H, Tausch E, Schneider C, et al.: Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut. Blood 142 (11): 961-972, 2023. (откроется в новой вкладке)
Hillmen P, Eichhorst B, Brown JR, et al.: Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. J Clin Oncol 41 (5): 1035-1045, 2023. (откроется в новой вкладке)
Shadman M, Flinn IW, Levy MY, et al.: Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol 10 (1): e35-e45, 2023. (откроется в новой вкладке)
Ma S, Seymour JF, Brander DM, et al.: Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. Blood 138 (10): 836-846, 2021. (откроется в новой вкладке)
Allan JN, Shanafelt T, Wiestner A, et al.: Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol 196 (4): 947-953, 2022. (откроется в новой вкладке)
Rogers KA, Huang Y, Ruppert AS, et al.: Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 38 (31): 3626-3637, 2020. (откроется в новой вкладке)
Soumerai JD, Mato AR, Dogan A, et al.: Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol 8 (12): e879-e890, 2021. (откроется в новой вкладке)
Huber H, Edenhofer S, von Tresckow J, et al.: Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood 139 (9): 1318-1329, 2022. (откроется в новой вкладке)
Wierda WG, Brown J, Abramson JS, et al.: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 22 (3): 175-204, 2024. (откроется в новой вкладке)
Ahn IE, Tian X, Ipe D, et al.: Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. J Clin Oncol 39 (6): 576-585, 2021. (откроется в новой вкладке)
Kovacs G, Robrecht S, Fink AM, et al.: Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. J Clin Oncol 34 (31): 3758-3765, 2016. (откроется в новой вкладке)
Al-Sawaf O, Zhang C, Lu T, et al.: Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J Clin Oncol 39 (36): 4049-4060, 2021. (откроется в новой вкладке)
Thompson PA, Srivastava J, Peterson C, et al.: Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 134 (22): 1951-1959, 2019. (откроется в новой вкладке)
Kater AP, Levin MD, Dubois J, et al.: Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol 23 (6): 818-828, 2022. (откроется в новой вкладке)
Kersting S, Dubois J, Nasserinejad K, et al.: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Lancet Haematol 9 (3): e190-e199, 2022. (откроется в новой вкладке)
Jones JA, Mato AR, Wierda WG, et al.: Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19 (1): 65-75, 2018. (откроется в новой вкладке)
Coutre S, Choi M, Furman RR, et al.: Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood 131 (15): 1704-1711, 2018. (откроется в новой вкладке)
Kater AP, Wu JQ, Kipps T, et al.: Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol 38 (34): 4042-4054, 2020. (откроется в новой вкладке)
Mato AR, Hill BT, Lamanna N, et al.: Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol 28 (5): 1050-1056, 2017. (откроется в новой вкладке)
Kater AP, Arslan Ö, Demirkan F, et al.: Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial. Lancet Oncol 25 (4): 463-473, 2024. (откроется в новой вкладке)
Thompson PA, Tam CS: Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood 141 (26): 3137-3142, 2023. (откроется в новой вкладке)
Mato AR, Woyach JA, Brown JR, et al.: Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med 389 (1): 33-44, 2023. (откроется в новой вкладке)
Wierda WG, Shah NN, Cheah CY, et al.: Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol 11 (9): e682-e692, 2024. (откроется в новой вкладке)
Porter DL, Levine BL, Kalos M, et al.: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365 (8): 725-33, 2011. (откроется в новой вкладке)
Turtle CJ, Hay KA, Hanafi LA, et al.: Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 35 (26): 3010-3020, 2017. (откроется в новой вкладке)
Frey NV, Gill S, Hexner EO, et al.: Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol 38 (25): 2862-2871, 2020. (откроется в новой вкладке)
Patel K, Danilov AV, Pagel JM: Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma. Blood 134 (19): 1573-1577, 2019. (откроется в новой вкладке)
Flinn IW, Hillmen P, Montillo M, et al.: The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood 132 (23): 2446-2455, 2018. (откроется в новой вкладке)
Chen CI, Bergsagel PL, Paul H, et al.: Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 29 (9): 1175-81, 2011. (откроется в новой вкладке)
Chanan-Khan A, Miller KC, Musial L, et al.: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24 (34): 5343-9, 2006. (откроется в новой вкладке)
Ferrajoli A, Lee BN, Schlette EJ, et al.: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111 (11): 5291-7, 2008. (откроется в новой вкладке)
Strati P, Keating MJ, Wierda WG, et al.: Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 122 (5): 734-7, 2013. (откроется в новой вкладке)
Wendtner CM, Hillmen P, Mahadevan D, et al.: Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 53 (3): 417-23, 2012. (откроется в новой вкладке)
Badoux XC, Keating MJ, Wen S, et al.: Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 31 (5): 584-91, 2013. (откроется в новой вкладке)
Takahashi K, Hu B, Wang F, et al.: Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131 (16): 1820-1832, 2018. (откроется в новой вкладке)
Moutouh-de Parseval LA, Weiss L, DeLap RJ, et al.: Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 25 (31): 5047, 2007. (откроется в новой вкладке)
Sutton L, Chevret S, Tournilhac O, et al.: Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood 117 (23): 6109-19, 2011. (откроется в новой вкладке)
Toze CL, Dalal CB, Nevill TJ, et al.: Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. Br J Haematol 158 (2): 174-85, 2012. (откроется в новой вкладке)
Khouri IF, Saliba RM, Admirand J, et al.: Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137 (4): 355-63, 2007. (откроется в новой вкладке)
Sorror ML, Storer BE, Sandmaier BM, et al.: Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 26 (30): 4912-20, 2008. (откроется в новой вкладке)
Schetelig J, van Biezen A, Brand R, et al.: Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 26 (31): 5094-100, 2008. (откроется в новой вкладке)
Malhotra P, Hogan WJ, Litzow MR, et al.: Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. Leuk Lymphoma 49 (9): 1724-30, 2008. (откроется в новой вкладке)
Dreger P, Döhner H, Ritgen M, et al.: Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116 (14): 2438-47, 2010. (откроется в новой вкладке)
Dreger P, Schnaiter A, Zenz T, et al.: TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood 121 (16): 3284-8, 2013. (откроется в новой вкладке)
van Oers MH, Kuliczkowski K, Smolej L, et al.: Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 16 (13): 1370-9, 2015. (откроется в новой вкладке)
Hillmen P, Robak T, Janssens A, et al.: Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 385 (9980): 1873-83, 2015. (откроется в новой вкладке)
Moreton P, Kennedy B, Lucas G, et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23 (13): 2971-9, 2005. (откроется в новой вкладке)
Parikh SA, Keating MJ, O'Brien S, et al.: Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 118 (8): 2062-8, 2011. (откроется в новой вкладке)
Pettitt AR, Jackson R, Carruthers S, et al.: Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 30 (14): 1647-55, 2012. (откроется в новой вкладке)
Stilgenbauer S, Zenz T, Winkler D, et al.: Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27 (24): 3994-4001, 2009. (откроется в новой вкладке)
Cortelezzi A, Pasquini MC, Gardellini A, et al.: Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 23 (11): 2027-33, 2009. (откроется в новой вкладке)
Osterborg A, Foà R, Bezares RF, et al.: Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23 (11): 1980-8, 2009. (откроется в новой вкладке)
Gritti G, Reda G, Maura F, et al.: Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma 53 (3): 424-9, 2012. (откроется в новой вкладке)
Lin TS, Donohue KA, Byrd JC, et al.: Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 28 (29): 4500-6, 2010. (откроется в новой вкладке)
Badoux XC, Keating MJ, Wang X, et al.: Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 118 (8): 2085-93, 2011. (откроется в новой вкладке)
Lepretre S, Aurran T, Mahé B, et al.: Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 119 (22): 5104-10, 2012. (откроется в новой вкладке)
Geisler CH, van T' Veer MB, Jurlander J, et al.: Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood 123 (21): 3255-62, 2014. (откроется в новой вкладке)
Al-Sawaf O, Zhang C, Tandon M, et al.: Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology 21 (9): 1188-1200, 2020. Cited in: Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia (откроется в новой вкладке)
Публикация не найдена в библиографии этого обзора.